| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27293SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22218SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-51691SS | |||
| Azide and BSA Free | NBP2-80611 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-125SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2068SS | |||
| Azide and BSA Free | NBP2-80554 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor Plus 488 | NBP1-47470AFP488 | |||
| Alexa Fluor Plus 555 | NBP1-47470AFP555 | |||
| Alexa Fluor Plus 594 | NBP1-47470AFP594 | |||
| Alexa Fluor Plus 647 | NBP1-47470AFP647 | |||
| Alexa Fluor Plus 680 | NBP1-47470AFP680 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47470SS | |||
| Azide and BSA Free | NBP2-80757 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-78039SS | |||
| Azide and BSA Free | NBP2-80921 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-317SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47339SS | |||
| Azide and BSA Free | NBP2-80748 | |||
![Western Blot: Snail Antibody [NBP2-27293] - Cisplatin-resistant gastric cancer cells exhibit an EMT-like phenotypic change. Epithelial marker E-cadherin, ZO1 and EMT-related transcription factor Snail were examined by Western blot. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27293-img0005.jpg "Western Blot: Snail Antibody [NBP2-27293] - Cisplatin-resistant gastric cancer cells exhibit an EMT-like phenotypic change. Epithelial marker E-cadherin, ZO1 and EMT-related transcription factor Snail were examined by Western blot. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: Snail Antibody [NBP2-27293] - Analysis of a FFPE tissue section of mouse placenta using 1:200 dilution of SNAIL antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP2-27293-img0007.jpg)
![Western Blot: Snail Antibody [NBP2-27293] - HER2 is overexpressed and both Herceptin incubation and siRNAs against HER2 reversed the EMT in cisplatin-resistant gastric cancer cells. Effects of Herceptin on levels of ZO1 and Snail. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27293-img0006.jpg)
![Immunohistochemistry-Paraffin: Snail Antibody [NBP2-27293] - Analysis of in FFPE human kidney tissue using this antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP2-27293-img0004.jpg)
![Simple Western: Snail Antibody [NBP2-27293] - Image shows a specific band for SNAIL in 0.5 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Snail-Antibody-Simple-Western-NBP2-27293-img0002.jpg)
![Western Blot: Snail Antibody - BSA Free [NBP2-27293] - SiRNAs against HER2 could abrogate the EMT phenotype & cell invasiveness in cisplatin-resistant gastric cancer cells.(A) Validation of silencing efficiency of HER2. Cells were transiently transfected with 50 nM HER2-specific siRNAs #1-#3 or a control siRNA for 48 h. (B) Knock-down of HER2 abrogated EMT morphology. Cells were transiently transfected with 50 nM specific siRNAs targeting HER2 for 48 h, Representative images of cellular morphology were shown. (C) Knock-down of HER2 abolished EMT phenotype. Cells were treated as in Fig. 4B. FITC-phalloidin staining of F-actin were performed & representative images were shown. (D) Effects of HER2 knock-down on the levels of ZO1 & Snail. (E) Effects of HER2 knock-down on cell migration. Representative images of transwell cell migration assay were shown. (F) Summary of Fig. 4E. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26846307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27293_rabbit-polyclonal-snail-antibody-310202416114759.jpg)
![Western Blot: Snail Antibody - BSA Free [NBP2-27293] - HER2 is overexpressed & both Herceptin incubation & siRNAs against HER2 reversed the EMT in cisplatin-resistant gastric cancer cells.(A) Western blot of HER2 in MGC803/DDP & AGS/DDP cell lines, & parental MGC803 & AGS cells. GAPDH was used as loading control. (B) Relative amplification of HER2 in parental & cisplatin-resistant cells. Results were presented as the mean ± SD of two independent experiments, *P < 0.05 compared with parental cells. (C) Herceptin incubation abrogated EMT morphology in MGC803/DDP cells. Representative images of cellular morphology of MGC803/DDP cells, plus parental MGC803 cells treated with Herceptin for 24 h were shown. Hercep represents Herceptin. (D) Herceptin incubation reversed EMT morphology in MGC803/DDP cells. Representative images of FITC-phalloidin staining of F-actin after 100 μg/ml Herceptin treatment for 24 h were shown. (E) Effects of Herceptin on levels of ZO1 & Snail. (F) CP724714 treatment abolished EMT-like cell morphology. Cells were incubated with 10 μM CP724714 for 24 h. Representative images of cellular morphology of were captured. (G) CP724714 treatment abrogated EMT-like cell morphology. Cells were treated as in Fig. 4F, FITC-phalloidin staining of F-actin was performed & typical images were shown. (H) Effects of CP724714 on ZO1 & Snail. (I) CP724714 inhibited the increased cell migration in cisplatin-resistant gastric cancer cells. Representative images were presented here. (J) CP724714 inhibited the increased cell migration in cisplatin-resistant gastric cancer cells. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26846307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27293_rabbit-polyclonal-snail-antibody-310202416113529.jpg)
![Western Blot: Glut2 Antibody [NBP2-22218] - Analysis of Glut2 in total lysates of MIN6 cells using anti-Glut2 (NBP2-22218) antibody at 1/500 dilution. Image was submitted via customer review.](http://images.novusbio.com/fullsize/Glut2-Antibody-Western-Blot-NBP2-22218-img0008.jpg "Western Blot: Glut2 Antibody [NBP2-22218] - Analysis of Glut2 in total lysates of MIN6 cells using anti-Glut2 (NBP2-22218) antibody at 1/500 dilution. Image was submitted via customer review.")
![Immunocytochemistry/Immunofluorescence: Glut2 Antibody [NBP2-22218] - Glut2 antibody was tested in HepG2 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/Glut2-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-22218-img0005.jpg)
![Immunohistochemistry-Paraffin: Glut2 Antibody [NBP2-22218] - Histology and immunostaining of pancreas in treated and untreated mice with STZ. (i, iv) H-E of a pancreatic islet in untreated and STZ-WT mice; (ii, v) and (iii,vi) reduction of Glut2 and insulin expression in STZ-WT mice compared to control mice. B. ( Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0105550), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Glut2-Antibody-Immunohistochemistry-Paraffin-NBP2-22218-img0009.jpg)
![Western Blot: Glut2 Antibody [NBP2-22218] - Analysis of Glucose Transporter GLUT2 in human pancreas.](http://images.novusbio.com/fullsize/Glut2-Antibody-Western-Blot-NBP2-22218-img0007.jpg)
![Immunohistochemistry: Glut2 Antibody [NBP2-22218] - Staining of Glucose Transporter GLUT2 in mouse liver.](http://images.novusbio.com/fullsize/Glut2-Antibody-Immunohistochemistry-NBP2-22218-img0006.jpg)
![Immunohistochemistry-Paraffin: Glut2 Antibody [NBP2-22218] - Histology and immunostaining of pancreas in treated and untreated mice with STZ. (i, iv) H-E of a pancreatic islet in untreated and STZ-K-RasV12 mice; (ii, v) and (iii,vi) reduction of Glut2 and insulin expression in STZ-K-RasV12 mice compared to untreated K-RasV12 control mice. Magnification 200x. Calibration bar: 50 um. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0105550), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Glut2-Antibody-Immunohistochemistry-Paraffin-NBP2-22218-img0010.jpg)
![Western Blot: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Carbonic Anhydrase IX mouse antibody against Hela (1) and A549 (2) cell lysates. Bands were detected at a molecular weight of approximately 50 kDa in both cell lines.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Western-Blot-NBP1-51691-img0006.jpg "Western Blot: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Carbonic Anhydrase IX mouse antibody against Hela (1) and A549 (2) cell lysates. Bands were detected at a molecular weight of approximately 50 kDa in both cell lines.")
![Immunohistochemistry-Paraffin: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Paraffin-embedded lung tissues (left) and colonic tissues (right) using Carbonic Anhydrase IX mouse antibody with DAB staining.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Immunohistochemistry-Paraffin-NBP1-51691-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody (2D3) - BSA Free [NBP1-51691] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with Carbonic Anhydrase IX/CA9 Antibody [2D3] (NBP1-51691) at 2ug/ml overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-51691-img0012.jpg)
![Flow Cytometry: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - A surface stain was performed on A431 cells with Carbonic Anhydrase IX/CA9 NBP1-51691 (blue) and a matched isotype control NBP2-27287 (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by DyLight488-conjugated anti-mouse secondary antibody.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Flow-Cytometry-NBP1-51691-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Mouse choroid stained with anti-Carbonic Anhydrase IX antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Immunocytochemistry-Immunofluorescence-NBP1-51691-img0011.jpg)
![Flow Cytometry: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Analysis of NTERA-2 cells using Carbonic Anhydrase IX mouse mAb (green) and negative control (purple).](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Flow-Cytometry-NBP1-51691-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b in HeLa Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:20 overnight at 4C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody. LAMP2 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0012.jpg "Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b in HeLa Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:20 overnight at 4C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody. LAMP2 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.")
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Normal deparaffinized Human placenta tissue tissues stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0015.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Both normal and cancer biopsies of deparaffinized Human prostate carcinoma tissues stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0016.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Analysis of 25ug of NRK cell lysates using anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0017.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Validation of subcellular fractionation and immunocytochemistry. RLC proteins are present at ER microsomes. Lysates from 7 DIV cortical neurons were subjected to differential centrifugation to isolate nuclear pellet (P1), postnuclear supernatant (PNS), mitochondrial pellet (P2), and ER microsomal pellet (P3), as depicted in the graphic on the right. Image collected and cropped by CiteAb from the following publication (www.onlinelibrary.wiley.com/doi/10.15252/embr.201744853) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:100 overnight at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody and nuclei with DAPI (blue) is shown.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0019.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Analysis of 10 ug of HeLa (left panel), NIH/3T3 (middle panel) and NRK (right panel) whole cell lysates using anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b (green) in NIH/3T3 cells.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0013.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Both normal and cancer biopsies of deparaffinized Human tonsils were stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0014.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Exposure of rat primary microglial cells (rPMs) to combined antiretroviral therapy (cART) cocktail resulted in impaired lysosomal function. rPMs were seeded into six-well plates & treated with cART (5 µM each of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), & dolutegravir (DTG)) for the indicated time periods. (A,B) Exposure of microglia to cART resulted in a significant decrease in expression of lysosomal-associated membrane protein 2 (LAMP2) at 6 to 24 h post-treatment. (C) Representative bar graph showing cART-mediated significantly increased lysosomal membrane permeabilization (LMP) (24 h). (D,E) Microglia exposed to cART demonstrated a significant decrease in levels of mature cathepsin D (mCTSD) at 24 h post-treatment. (F) Representative bar graph showing exposure of cART significantly reduced the CTSD activity in rPMs (24 h). (G) Representative bar graph showing cART-mediated increased lysosomal pH in rPMs. (H,I) Acridine orange staining showing increased green color & reduced red color in cART-treated rPMs. H2O2 was used as a positive control for lysosome damage. Data is from three independent experiments. Actin beta (ACTB) served as a protein loading control for western blots. Data are expressed as means ± SEM & were analyzed using student t-test or one-way ANOVA. *, p < 0.05 vs. control; N.S., non-significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31569373), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-591_rabbit-polyclonal-lamp-2-cd107b-antibody-310202416175213.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - HSPA overexpression abrogated cART-mediated impairment of lysosomal function. Control rPMs & heat shock protein family A (HSPA) overexpressing rPMs were seeded into six-well plates subjected to various treatments for 24 h. Protein homogenates were prepared for the detection of the indicated molecules. (A,B) Representative western blots showing overexpressing HSPA in rPMs reversed cART-mediated downregulation of LAMP2 & mCTSD expression levels. (C) Representative bar graph showing overexpression of HSPA in rPMs protected lysosomal pH. (D,E) Representative bar graphs showing HSPA protected LMP (D), & CTSD activity (E) in cART-treated rPMs. For all western blots, ACTB served as a protein loading control. Data is from three independent experiments & is expressed as means ± SEM & were analyzed using student t-test or one-way ANOVA. *, p < 0.05 vs. control; #, p < 0.05 vs. cART. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31569373), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-591_rabbit-polyclonal-lamp-2-cd107b-antibody-31020241618933.jpg)
![Immunocytochemistry/Immunofluorescence: CFTR Antibody (CF3) [NB300-511] - CFTR staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing CFTR at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight 488 conjugated antibody.](http://images.novusbio.com/fullsize/CFTR-Antibody-CF3-Immunocytochemistry-Immunofluorescence-NB300-511-img0006.jpg "Immunocytochemistry/Immunofluorescence: CFTR Antibody (CF3) [NB300-511] - CFTR staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing CFTR at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight 488 conjugated antibody.")
![Immunohistochemistry-Paraffin: CFTR Antibody (CF3) [NB300-511] - Normal biopsies of deparaffinized Human tonsil tissue.](http://images.novusbio.com/fullsize/CFTR-Antibody-CF3-Immunohistochemistry-Paraffin-NB300-511-img0003.jpg)
![Flow Cytometry: CFTR Antibody (CF3) [NB300-511] - Human airway epithelial cells stained with CFTR (CF3) coupled with goat anti-mouse FITC conjugated secondary antibody. Flow cytometry image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CFTR-Antibody-CF3-Flow-Cytometry-NB300-511-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: CFTR Antibody (CF3) [NB300-511] - Staining of human pancreas cryosection (200x). Alpha cells are strongly labeled. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CFTR-Antibody-CF3-Immunocytochemistry-Immunofluorescence-NB300-511-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CFTR Antibody (CF3) [NB300-511] - CFTR staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing CFTR at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight 488 conjugated antibody.](http://images.novusbio.com/fullsize/CFTR-Antibody-CF3-Immunocytochemistry-Immunofluorescence-NB300-511-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: CFTR Antibody (CF3) [NB300-511] - CFTR staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing CFTR at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight 488 conjugated antibody.](http://images.novusbio.com/fullsize/CFTR-Antibody-CF3-Immunocytochemistry-Immunofluorescence-NB300-511-img0005.jpg)
![Immunohistochemistry-Paraffin: CFTR Antibody (CF3) [NB300-511] - Cancer biopsies of deparaffinized Human colon carcinoma tissue.](http://images.novusbio.com/fullsize/CFTR-Antibody-CF3-Immunohistochemistry-Paraffin-NB300-511-img0001.jpg)
![Immunohistochemistry-Paraffin: CFTR Antibody (CF3) [NB300-511] - Normal biopsies of deparaffinized Human pancreas tissue.](http://images.novusbio.com/fullsize/CFTR-Antibody-CF3-Immunohistochemistry-Paraffin-NB300-511-img0002.jpg)
![Western Blot: PER2 Antibody [NB100-125] - Western Blot Usage of NB100-125. Image submitted via verified customer review.](http://images.novusbio.com/fullsize/PER2-Antibody-Western-Blot-NB100-125-img0003.jpg "Western Blot: PER2 Antibody [NB100-125] - Western Blot Usage of NB100-125. Image submitted via verified customer review.")
![Immunocytochemistry/Immunofluorescence: PER2 Antibody [NB100-125] - U-87 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-PER2 Antibody at 5 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/PER2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-125-img0005.jpg)
![Western Blot: PER2 Antibody [NB100-125] - WB analysis of PER2 expression on ARPE-19 whole cell lysate.](http://images.novusbio.com/fullsize/PER2-Antibody-Western-Blot-NB100-125-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: PER2 Antibody [NB100-125] - The PER2 antibody was tested in ARPE-19 cells at a 1:250 dilution against Dylight 488 (Green). Alpha-tubulin and nuclei were counterstained against Dylight 550 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/PER2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-125-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: PER2 Antibody [NB100-125] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-PER2 Antibody at 5 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/PER2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-125-img0004.jpg)
![Western Blot: ABCA1 Antibody (HJ1) [NB100-2068] - Detection of ABCA1 in wildtype liver tissue (in RIPA) Lane 1: KO mouse liver tissue. Lane 2: WT mouse liver tissue.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Western-Blot-NB100-2068-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: ABCA1 Antibody (HJ1) [NB100-2068] - Detection of ABCA1 in wildtype liver tissue (in RIPA) Lane 1: KO mouse liver tissue. Lane 2: WT mouse liver tissue.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: ABCA1 Antibody (HJ1) [NB100-2068] - Analysis of ABCA1 in human renal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Immunohistochemistry-NB100-2068-img0006.jpg)
![Flow Cytometry: ABCA1 Antibody (HJ1) [NB100-2068] - Staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using ABCA1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Flow-Cytometry-NB100-2068-img0010.jpg)
![Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of GSK-3 beta in mouse beta cell line (betaTC3) using anti-GSK-3 beta antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Western-Blot-NBP1-47470-img0012.jpg "Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of GSK-3 beta in mouse beta cell line (betaTC3) using anti-GSK-3 beta antibody. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of NIH/3T3 (left) and U251 (right) cells using GSK3 beta mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunocytochemistry-Immunofluorescence-NBP1-47470-img0006.jpg)
![Immunohistochemistry: GSK-3 beta Antibody (3D10) [NBP1-47470] - Fap1-inhibition with SLV peptide increases phosphorylation of Fap1-substrates Fas and GSK-3 beta in a murine xenograft model. SW620 cells injected into flanks of athymic Nude mice & tumor volume was checked biweekly. Mice treated weekly with oxaliplatin (days 0, 7 and 14) & injected daily with Fap1 blocking SLV peptide, VLS control peptide, or treated with SLV or VLS peptide alone (n=12). Tumors were simultaneously harvested when control tumors were >2,000 mm3. SLV peptide increases Gsk3-phosphorylation with/without oxaliplatin. IF detection of total versus phospho- GSK-3 beta performed with DAPI staining of nuclei (areas without gland formation were selected). Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.25401), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunohistochemistry-NBP1-47470-img0014.jpg)
![Flow Cytometry: GSK-3 beta Antibody (3D10) [NBP1-47470] - An intracellular stain was performed on HeLa cells with GSK-3 beta (3D10) antibody NBP1-47470PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Flow-Cytometry-NBP1-47470-img0013.jpg)
![Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis using GSK3 beta mouse mAb against A549 (1), K562 (2), PC-12 (3), NIH/3T3 (4), and HEK293 (5) cell lysates.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Western-Blot-NBP1-47470-img0008.jpg)
![Immunohistochemistry-Paraffin: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of paraffin-embedded human lung cancer (left) and breast cancer tissues (right) using GSK3 beta mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunohistochemistry-Paraffin-NBP1-47470-img0007.jpg)
![Flow Cytometry: GSK-3 beta Antibody (3D10) [NBP1-47470] - Flow cytometric analysis of Hela cells using GSK3 beta mouse mAb (green) and negative control (purple).](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Flow-Cytometry-NBP1-47470-img0005.jpg)
![Simple Western: GSK-3 beta Antibody (3D10) [NBP1-47470] - Simple Western lane view shows a specific band for GSK-3 Beta in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Simple-Western-NBP1-47470-img0009.jpg)
![Simple Western: GSK-3 beta Antibody (3D10) [NBP1-47470] - Simple western analysis of mouse brain tissue (striatum) from 4 month old Tg4150 and wildtype mice. Image courtesy of Dr. Brandi Wasek-Patterson at Baylor Research Institute, Institute of Metabolic Disease.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Simple-Western-NBP1-47470-img0010.jpg)
![Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] - Fap1-inhibition with SLV peptide increases Fas & Gsk3 beta phosphorylation in CD133+ cells in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice & tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 & 14) & injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases Fas phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Fas or CD133 was performed with DAPI staining of nuclei. (B) SLV peptide increases Gsk3 beta phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Gsk3 beta or CD133 was performed with DAPI staining of nuclei. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29899829), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47470_mouse-monoclonal-gsk-3-beta-antibody-3d10-310202416171462.jpg)
![Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] - Fap1-inhibition with SLV peptide increases phosphorylation of Fap1-substrates Fas & Gsk3 beta in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice & tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 & 14) & injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases gland formation in xenograft tumors with or without oxaliplatin. Histology was analyzed by hematoxylin/ eosin staining. Fap1 expression was determined by immunofluorescence. Relative fluorescent intensity (RFI) of Fap1 staining is indicated below relevant panels. (B) SLV peptide increases Fas-phosphorylation in xenograft tumors with or without by oxaliplatin. Immunofluorescent detection of total versus phospho-Fas was performed with DAPI staining of nuclei. Areas without gland formation were selected for this study. (C) SLV peptide increases Gsk3 beta -phosphorylation with or without oxaliplatin. Immunofluorescent detection of total versus phospho- Gsk3 beta was performed with DAPI staining of nuclei. Areas without gland formation were selected for this study. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29899829), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47470_mouse-monoclonal-gsk-3-beta-antibody-3d10-3102024161604.jpg)
![Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Western-Blot-NB100-78039-img0006.jpg "Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.")
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Human tonsil tissue stained with PSGL-1/CD162 Antibody (HECA-452) at 5ug/mL, and Leica Refine DAB kit. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PSGL-1-CD162-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0014.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD3+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody [F0101B, R&D Systems]. A co-stain was performed using CD3 antibody NBP2-25186APC.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0008.jpg)
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human breast adenocarcinoma using CLA antibody (clone HECA-452) at 5 ug/ml concentration. The antibody generated a membrane-cytoplasmic staining in the cancerous cells of breast adenocarcinoma. Note:- Besides lymphocytes, CLA has been shown to be present on cells of normal endometrium as well as breast cancer tissues (PMID 19625313 and 22970241).](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0004.jpg)
![Flow Cytometry: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Human peripheral blood lymphocytes stained with purified HECA-452, followed by anti-mouse IgG FITC](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cytometry-NB100-78039-img0005.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD14+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by rat-Dylight 488 conjugated secondary antibody. A co-stain was performed using CD14 antibody NB100-77758AF488.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0007.jpg)
![Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NB100-59740] - (0.003ug/ml) staining of Mouse (A) and Rat (B) Liver lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/nb100-59740_goat-polyclonal-arginase-1-arg1-liver-arginase-antibody-1652023918335.jpg "Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NB100-59740] - (0.003ug/ml) staining of Mouse (A) and Rat (B) Liver lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.")
![Western blot results. (A) Representative Western blot and quantitative analysis of protein levels of Iba‐1, iNOS, ARG1, IL‐1 beta , and TNF‐ alpha in PFC tissues, n = 6. (B) Relative level of Iba‐1 protein in PFC (fold change relative to beta ‐actin protein level). (C) The relative level of iNOS protein in PFC (fold change relative to beta ‐actin protein level). (D) The relative level of ARG1 protein in PFC (fold change relative to beta ‐actin protein level). (E) The relative level of IL‐1 beta protein in PFC (fold change relative to beta ‐actin protein level). (F) The relative level of TNF‐ alpha protein in PFC (fold change relative to beta ‐actin protein level). *p < 0.05 versus Con group. ARG1, arginase‐1; IL‐1 beta , interleukin‐1 beta ; iNOS, inducible nitric oxide synthase; PFC, prefrontal cortex; TNF‐ alpha , tumor necrosis factor‐ alpha [Color figure can be viewed at wileyonlinelibrary.com] Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37786559), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-59740_goat-polyclonal-arginase-1-arg1-liver-arginase-antibody-western-blot-132202618165113.jpg)
![Western Blot: xCT Antibody [NB300-317] - Total protein from human HeLa, Huvec, HCT-116 and A549 cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/xCT-Antibody-Western-Blot-NB300-317-img0011.jpg "Western Blot: xCT Antibody [NB300-317] - Total protein from human HeLa, Huvec, HCT-116 and A549 cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: xCT Antibody [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped and form clusters in MS patients, whereas in controls, CD68+ cells appear isolated and long shaped. Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/xCT-Antibody-Immunohistochemistry-Paraffin-NB300-317-img0015.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: xCT Antibody [NB300-317] - Total protein from Human HeLa cells treated with and without 0.1 mM Diethyl Maleate for 24 hours was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-xCT in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the increase in xCT expression with treatment.](http://images.novusbio.com/fullsize/xCT-Antibody-Western-Blot-NB300-317-img0012.jpg)
![Flow Cytometry: xCT Antibody [NB300-317] - An intracellular stain was performed on HeLa cells with NB300-317G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-317-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: xCT Antibody [NB300-317] - xCT antibody was tested in HepG2 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/xCT-Antibody-Immunocytochemistry-Immunofluorescence-NB300-317-img0005.jpg)
![Flow Cytometry: xCT Antibody [NB300-317] - An intracellular stain was performed on HeLa with NB300-317 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG APC-conjugated Secondary Antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/xCT-Antibody-Flow-Cytometry-NB300-317-img0013.jpg)
![Simple Western: xCT Antibody [NB300-317] - (1) ladder, (2) no lysate + xCT, 100ug/ml, (3) human brain frontal cortex membrane lysate,no primary antibody, (4-7) human brain lysates, 0.03mg/ml, xCT, 100ug/ml.](http://images.novusbio.com/fullsize/xCT-Antibody-Simple-Western-NB300-317-img0010.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. A. Triple immunofluorescence staining for xCT (green), CD68 (red) & Hoechst 33258 (blue) in spinal cord of control (left) & MS patients (right). A high expression of xCT was detected in CD68+ infiltrating macrophages (arrows) associated with blood vessels, which are virtually absent in controls. Note that overall xCT expression is enhanced in MS tissue. B. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped & form clusters in MS patients, whereas in controls, CD68+ cells appear isolated & long shaped. Scale bar = 50 μm. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202415284530.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is enhanced in CD68+ cells from MS spinal cord. A. Triple immunofluorescence staining for xCT (green), CD68 (red) & Hoechst 33258 (blue) in spinal cord of control (left) & MS patients (right). A high expression of xCT was detected in CD68+ infiltrating macrophages (arrows) associated with blood vessels, which are virtually absent in controls. Note that overall xCT expression is enhanced in MS tissue. B. CD68+ cells (arrows) show enhanced xCT expression in MS patients as compared to controls. CD68+ macrophages are round shaped & form clusters in MS patients, whereas in controls, CD68+ cells appear isolated & long shaped. Scale bar = 50 μm. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202415392541.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is increased in the CNS of rats with EAE. A. Histogram showing the neurological score during the course of acute EAE induced in Lewis rats by immunization with myelin basic protein. The peak of neurological disability was at day 14 post-immunization, which was selected for obtaining tissue samples. B. xCT mRNA (left) & protein (right) expression in spinal cord from control & acute EAE rats, as assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5-6). C. Double immunofluorescence for xCT (green) & OX-42 (red), a marker of microglia & infiltrating macrophages. OX42+ cells express high xCT levels in acute EAE. Both meninges (asterisk in top) & infiltrating cells (bottom) in inflammatory foci show high levels of xCT in rat spinal cord with EAE as compared to controls. D. Microglial cells (OX42+ cells) of EAE rats have higher xCT levels in spinal cord than controls. Notice the difference between resting microglia in control rats, with ramified morphology (arrows in control) & microglia in EAE showing round shaped morphology, characteristic of its activated state (arrows in EAE). Scale bar = 20 μm.E. xCT mRNA (left) & protein (right) expression in spinal cord from control & chronic EAE mice, assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5). Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202416205190.jpg)
![Immunocytochemistry/ Immunofluorescence: xCT Antibody - BSA Free [NB300-317] - xCT expression is increased in the CNS of rats with EAE. A. Histogram showing the neurological score during the course of acute EAE induced in Lewis rats by immunization with myelin basic protein. The peak of neurological disability was at day 14 post-immunization, which was selected for obtaining tissue samples. B. xCT mRNA (left) & protein (right) expression in spinal cord from control & acute EAE rats, as assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5-6). C. Double immunofluorescence for xCT (green) & OX-42 (red), a marker of microglia & infiltrating macrophages. OX42+ cells express high xCT levels in acute EAE. Both meninges (asterisk in top) & infiltrating cells (bottom) in inflammatory foci show high levels of xCT in rat spinal cord with EAE as compared to controls. D. Microglial cells (OX42+ cells) of EAE rats have higher xCT levels in spinal cord than controls. Notice the difference between resting microglia in control rats, with ramified morphology (arrows in control) & microglia in EAE showing round shaped morphology, characteristic of its activated state (arrows in EAE). Scale bar = 20 μm.E. xCT mRNA (left) & protein (right) expression in spinal cord from control & chronic EAE mice, assessed by qPCR & Western blot analysis. Data are referred to mean expression level of controls (n = 5). Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-8-63), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-317_rabbit-polyclonal-xct-antibody-310202416205138.jpg)
![Western Blot: GAPDH Antibody (1A10) [NBP1-47339] - Analaysis using anti-GAPDH mAb against Hela (1), A549 (2), A431 (3), MCF-7 (4), K562 (5), Jurkat (6), HL60 (7), SKN-SH (8) and SKBR-3 (9) cell lysate. Theoretical molecular weight: 36 kDa.](http://images.novusbio.com/fullsize/GAPDH-Antibody-1A10-Western-Blot-NBP1-47339-img0006.jpg "Western Blot: GAPDH Antibody (1A10) [NBP1-47339] - Analaysis using anti-GAPDH mAb against Hela (1), A549 (2), A431 (3), MCF-7 (4), K562 (5), Jurkat (6), HL60 (7), SKN-SH (8) and SKBR-3 (9) cell lysate. Theoretical molecular weight: 36 kDa.")
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody (1A10) [NBP1-47339] - Analysis of methanol-fixed HepG2 (left) and HeLa (right) cells using anti-GAPDH mAb (green), showing cytoplasmic localization. DRAQ5 fluorescent DNA dye (blue).](http://images.novusbio.com/fullsize/GAPDH-Antibody-1A10-Immunocytochemistry-Immunofluorescence-NBP1-47339-img0004.jpg)
![Flow Cytometry: GAPDH Antibody (1A10) [NBP1-47339] - An intracellular stain was performed on U-87 cells with GAPDH [1A10] Antibody NBP1-47339AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/GAPDH-Antibody-1A10-Flow-Cytometry-NBP1-47339-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody (1A10) [NBP1-47339] - GAPDH was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using 2 ug/mL of mouse anti-GAPDH monoclonal (NB300-328), 2 ug/mL mL of mouse anti- GAPDH monoclonal (NBP1-47339). Cells were stained using the appropriate secondary antibody donkey anti-mouse IgG-NL557 (NL007) and counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/GAPDH-Antibody-1A10-Immunocytochemistry-Immunofluorescence-NBP1-47339-img0008.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (1A10) [NBP1-47339] - Analysis of paraffin-embedded human breast carcinoma (left) and kidney carcinoma (right), showing cytoplasmic localization using anti-GAPDH mAb with DAB staining.](http://images.novusbio.com/fullsize/GAPDH-Antibody-1A10-Immunohistochemistry-Paraffin-NBP1-47339-img0005.jpg)
![Simple Western: GAPDH Antibody (1A10) [NBP1-47339] - Lane view shows a specific band for GAPDH in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Note: band observed higher than predicted 36 kDa molecular weight.](http://images.novusbio.com/fullsize/GAPDH-Antibody-1A10-Simple-Western-NBP1-47339-img0007.jpg)
